尚榮醫療(002551.SZ)業績快報:2020年淨利升175.82%至1.65億元
格隆匯2月26日丨尚榮醫療(002551.SZ)披露2020年度業績快報,報吿期內,公司實現營業收入22.28億元,同比增長45.54%;營業利潤4.04億元,同比增長459.81%;歸屬於上市公司股東的淨利潤1.65億元,同比增長175.82%。業績大幅增長的主要原因系:
1、報吿期內受新冠疫情影響,海內外一次性醫用防護用品需求聚增,公司控股子公司合肥普爾德醫療用品有限公司訂單持續處於飽和狀態,使得公司防護用品銷售收入及營業利潤均大幅增加;
2、報吿期內公司業務回款較上年同期有較大的增長,應收賬款期末餘額較上年末減少,計提的應收賬款減值準備同比減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.